Advertisement
Screener

ANNEXON, INC. (ANNX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

2.8 / 5 stars · 68/120 Roast Me

ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

ANNEXON, INC. (ANNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 91.90% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-08-12

  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-06-30 was 91.90%, a 2.03% decline year-over-year.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2026-03-31 was 92.30%, a 1.60% decline year-over-year.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-06-30 was 93.80%, a 4.09% decline year-over-year.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 93.80%, a 2.49% decline year-over-year.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 93.80%, a 6.01% decline from fiscal 2024.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 99.80%, a 21.12% increase from fiscal 2023.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 82.40%, a 4.07% decline from fiscal 2022.
  • ANNEXON, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 85.90%, a 5.29% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month as first filed
2026-06-3091.90%
10-Q · filed 2026-08-12
92.30%
10-Q · filed 2026-08-12
2026-03-3192.30%
10-Q · filed 2026-05-07
2025-12-3193.80%
10-K · filed 2026-03-30
2025-09-3093.80%
10-Q · filed 2025-11-10
2025-06-3093.80%
10-Q · filed 2026-08-12
93.80%
10-Q · filed 2026-08-12
2025-03-3193.80%
10-Q · filed 2026-05-07
2024-12-3199.80%
10-K · filed 2026-03-30
2024-09-3097.60%
10-Q · filed 2025-11-10
97.80%
10-Q · filed 2025-11-10
2024-06-3097.80%
10-Q · filed 2025-08-14
97.80%
10-Q · filed 2025-08-14
2024-03-3196.20%
10-Q · filed 2025-05-12
2023-12-3182.40%
10-K · filed 2025-03-03
2023-09-3081.90%
10-Q · filed 2024-11-14
82.40%
10-Q · filed 2024-11-14
2023-06-3082.40%
10-Q · filed 2024-08-12
82.40%
10-Q · filed 2024-08-12
2023-03-3181.50%
10-Q · filed 2024-05-13
82.00%
10-Q · filed 2023-05-08
2022-12-3185.90%
10-K · filed 2024-03-26
2022-09-3082.70%
10-Q · filed 2023-11-13
82.80%
10-Q · filed 2023-11-13
2022-06-3082.80%
10-Q · filed 2023-08-07
82.80%
10-Q · filed 2023-08-07
2022-03-3182.00%
10-Q · filed 2023-05-08
2021-12-3190.70%
10-K · filed 2023-03-06
91.00%
10-K · filed 2022-03-01
2021-09-3089.00%
10-Q · filed 2022-11-03
90.70%
10-Q · filed 2022-11-03
2021-06-3090.70%
10-Q · filed 2022-08-08
90.70%
10-Q · filed 2022-08-08
2020-12-3193.00%
10-K · filed 2022-03-01
2020-09-3093.00%
10-Q · filed 2021-11-09
93.00%
10-Q · filed 2021-11-09
2019-12-3177.00%
10-K · filed 2021-03-25
2019-09-3077.00%
10-Q · filed 2020-11-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50